Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
Would you continue tarlatamab in CNS-only progression of small cell cancer if there is no systemic disease?
Related Questions
Would you consider adjuvant osimertinib for NSCLC with an EGFR E746_S752delinsV exon 19 mutation?
What are your top takeaways in Thoracic Cancers from ASCO 2025?
Would a patient with a resected NSCLC mass under 3 cm, without lymph node involvement or distant metastases, but with visceral invasion identified on pathology, benefit from adjuvant therapy?
In stage IV oligometastatic NSCLC, when considering local consolidative therapies to the primary tumor, do providers typically stage the mediastinum at diagnosis or after initial systemic therapy (assuming no progression)?
Would you switch from carboplatin/etoposide to cisplatin/etoposide in an LS-SCLC patient who initially declines cisplatin but subsequently agrees to it?
Would you give adjuvant sunvozertinib to patients with stage II-III NSCLC with an EGFR exon 20 insertion mutation?
Are you planning to start running IHC HER2 testing on all tumor types, even those where HER2 overexpression is less typical, in light of tumor agnostic approval of trastuzumab deruxtecan?
What is the role of consolidative durvalumab and prophylactic cranial irradiation in patients with stage I small cell lung cancer?
When, if at all, do you utilize neoadjuvant chemotherapy alone for resectable, Stage II NSCLC with mutations such as EGFR or ALK?
How do you prioritize treatment in a lung cancer patient who has HER2 IHC3+ along with other actionable mutations that have tumor-specific drugs available?
